Scott Dunseth Myers
CIK 1356256 · Chief Executive Officer · last filed 2026-06-18
Scott Dunseth Myers is a Chief Executive Officer who has filed 54 SEC Form 4 insider transactions across 10 companies since 2016. The most recent filing, for ZNTL, was dated Jun 18, 2026. Across all open-market trades the lifetime net is +$555.0K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $6.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$6.89M
10
54
$555.0K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZNTL | Director | 395,895 | $4.62 | $1.83M | $29.4K | 4 | 2026-06-18 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Director | 0 | $15.50 | $0 | $41.1K | 7 | 2026-02-10 |
| Harpoon Therapeutics, Inc. (HARP) Delisted | Director | 0 | $23.01 | $0 | $0 | 13 | 2024-03-11 |
| RNAC | Director | — | $7.65 | — | $0 | 1 | 2023-11-15 |
| VRDN | Chief Executive Officer | 259,500 | $19.51 | $5.06M | $261.8K | 3 | 2023-04-12 |
| Cartesian Therapeutics, Inc. (SELB) Delisted | Director | 80,845 | $0.88 | $71.2K | $0 | 7 | 2023-01-04 |
| Trillium Therapeutics Inc. (TRIL) Delisted | Director | — | $19.86 | — | $0 | 1 | 2021-05-05 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | President & CEO | — | — | — | $0 | 2 | 2020-11-17 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | President and CEO | 56,787 | — | — | $222.7K | 12 | 2018-02-02 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | President and CEO | — | — | — | $0 | 1 | 2016-04-06 |
Recent Filings
54 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-18 | ZNTL | Grant (A) | +57,100 | $0 | EDGAR |
| 2026-02-10 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Mixed | −35,004 | $0 | EDGAR |
| 2025-08-25 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Buy (P) | +3,800 | $41.1K | EDGAR |
| 2025-06-18 | ZNTL | Grant (A) | +57,603 | $0 | EDGAR |
| 2025-06-13 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Grant (A) | +5,758 | $0 | EDGAR |
| 2025-04-30 | ZNTL | Buy (P) | +21,000 | $29.4K | EDGAR |
| 2024-11-13 | ZNTL | Grant (A) | +260,192 | $0 | EDGAR |
| 2024-05-28 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Grant (A) | +5,357 | $0 | EDGAR |
| 2024-03-11 | Harpoon Therapeutics, Inc. (HARP) Delisted | Disp (D) | −22,665 | $0 | EDGAR |
| 2024-01-03 | Harpoon Therapeutics, Inc. (HARP) Delisted | Grant (A) | +2,048 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.